Cubist Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. (TEVA) have resolved their dispute by Cubist agreeing to license its antibiotic Cubicin to Teva . Under the agreement Teva can start selling its generic version in June 2018 if Cubist is granted a six-month extension of marketing protection for pediatric use.
The patent is due to expire in September 2019. Without pediatric clearance, Teva may sell Cubicin starting in December 2017.
The case: Cubist Pharmaceuticals Inc. (CBST), v. Teva Parenteral Medicines Inc., 1:09-cv-00189-GMS, U.S. District Court, District of Delaware (Wilmington).